Sionna Therapeutics, Inc. SION

Annual Quarterly

No annual revenue total was found in SIONNA THERAPEUTICS, INC.'s SEC filings.

Sionna Therapeutics, Inc. (SION) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$66.7 million. As of Jun 30, 2026 it held $63.3 million in cash and investments and $8.1 million in total debt.

Revenue
—
Net income (TTM)
$-97.38M
Operating cash flow (TTM)
$-75.92M
Free cash flow (TTM)
$-76.21M
EPS (TTM)
$-2.17
Dividend per share
None
Shares outstanding
45.00M
Net cash
$55.25M
as of Jun 30, 2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
SION (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Waltham, MA
SEC filer status
, Emerging growth company
SEC CIK
2036042

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.

FY 2025
Dec 31, 2025
Operating income
-$89.0M
Net income
-$75.3M
Diluted EPS
-$1.88
Operating cash flow
-$66.3M
Free cash flow
-$66.7M
Total assets
$326.0M
Total liabilities
$19.1M
Stockholders' equity
$306.8M
Cash and investments
$58.5M
Total debt
$8.7M

Recent SEC filings

Form Description Filed Period
8-K Current report
Exit or restructuring costs, Officer or director change, Other events
 Sep 14, 2026 Sep 9, 2026
8-K Current report
Other events
 Aug 10, 2026 Aug 10, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 6, 2026 Aug 6, 2026
8-K Current report
Shareholder vote results
 Jun 18, 2026 Jun 17, 2026
10-Q Quarterly report May 12, 2026 Mar 31, 2026

All 231 Sionna Therapeutics, Inc. SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.